US Special Situations: US Renal Care looks to unwind asset strip move from 2023 LME in latest refi plan – Report
Veronica Graff: Reporter
27 July 2026
- How the company’s refinancing strategy could reshape lender protections and recovery prospects.
- Why previously separated assets are becoming central to ongoing restructuring discussions.
- What credit investors should monitor as financing terms continue to evolve.
- How operational performance is influencing creditor confidence and market sentiment.
- Where key risks and opportunities may emerge as the capital structure changes.
Overview
US Renal Care is evaluating options to reshape its financing framework. Discussions focus on addressing obligations while improving support from lenders.
Interest is building around a proposed transaction involving multiple funding sources. The process reflects ongoing efforts to strengthen financial flexibility.
Certain assets could return to creditor oversight under the new structure. This shift may reverse elements of a previous restructuring strategy.
Meanwhile, market participants are closely tracking developments surrounding the refinancing process. Expectations continue to evolve as discussions progress.
However, recent operating performance has supported a more constructive credit outlook. Investors remain focused on execution and longer-term stability.



